Picture [iito] Made Without Love 650x80px
Document › Details

Lysogene S.A.. (3/12/20). "Press Release: Lysogene Completes €7.7 Million Capital Increase in a Placement Led by Leading Healthcare Investor OrbiMed and Lysogene Shareholder and Partner Sarepta [Not for US, CA, AU or JP]". Paris.

Organisations Organisation Lysogene S.A. (Euronext Paris: LYS)
  Organisation 2 OrbiMed Advisors LLC
  Group OrbiMed (Group)
Products Product LYS-GM101 (gene therapy for GM1 Gangliosidosis)
  Product 2 venture capital
Index terms Index term Lysogene–SEVERAL: investment, 202003 capital increase €7.7m led by OrbiMed Advisors + incl Sarepta Therapeutics at €2.83/share
  Index term 2 Lysogene–Sarepta: investment, 202003 capital increase totalling €7.7m incl €538k from existing + co-investor Sarepta Therapeutics
Persons Person Aiach, Karen (Lysogene 201206 CEO + Founder)
  Person 2 Durant des Aulnois, Stéphane (Lysogene 201910– CFO before Ipsen + LaSalle Investment + Calyon Americas)

Record changed: 2020-07-07


Picture [iito] Plain Stupid Simple 650x80px

More documents for Lysogene S.A. (Euronext Paris: LYS)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top